Adrenocortical carcinoma

Cancer Treatment and Research

Volumn 153, Issue , 2010, Pages 187-210

  Sidhu, Stan B ^a,b   Soon, Patsy S H ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CISPLATIN; CORTICOTROPIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHIONINE; MITOTANE; PROTEIN CYP21B; PROTEIN P53; SOMATOMEDIN B; STEROID 21 MONOOXYGENASE; STREPTOZOCIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG MECHANISM; FAMILIAL CANCER; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 77953674306     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0857-5_11     Document Type: Review

References (137)

1. Abecassis M, McLoughlin MJ, Langer B, Kudlow JE (1985) Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg 149:783-788
2. Bovio S, Cataldi A, Reimondo G et al (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298-302
3. NIH (2002) NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 19:1-25
4. Allolio B, Fassnacht M (2006) Adrenocortical Carcinoma: Clinical Update. J Clin Endocrinol Metab 91:2027-2037
5. Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130-3136
6. Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897
7. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P (1996) The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119:161-170
8. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM (1995) Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75:2587-2591
9. Tauchmanova L, Colao A, Marzano LA et al (2004) Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 28:896-903
10. Wooten MD, King DK (1993) Adrenal cortical carcinoma Epidemiology and treatment with mitotane and a review of the literature. Cancer 72:3145-3155
11. Sidhu S, Sywak M, Robinson B, Delbridge L (2004) Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 16:13-18
12. Didolkar MS, Bescher RA, Elias EG, Moore RH (1981) Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 47:2153-2161
13. Kasperlik-Zeluska AA, Roslonowska E, Slowinska-Srzednicka J et al (1997) Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 46:29-37
14. Luton JP, Cerdas S, Billaud L et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195-1201
15. Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC (1983) Adrenal cortical carcinoma - a continuing challenge. Surgery 94:926-931
16. Allolio B, Hahner S, Weismann D, Fassnacht M (2004) Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60:273-287
17. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR (2000) Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175:1411-1415
18. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR (2000) Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217:798-802
19. Copeland PM (1999) The incidentally discovered adrenal mass: an update. Endocrinologist 9:415-423
20. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ (2005) Adrenocortical carcinoma: a single institution experience. Am Surg 71:90-94
21. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872-878
22. Macfarlane DA (1958) Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155-186
23. Sullivan M, Boileau M, Hodges CV (1978) Adrenal cortical carcinoma. J Urol 120:660-665
24. Cohn K, Gottesman L, Brennan M (1986) Adrenocortical carcinoma. Surgery 100:1170-1177
25. Kendrick ML, Lloyd R, Erickson L et al (2001) Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 136:543-549
26. Shen WT, Sturgeon C, Duh QY (2005) From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol 89:186-192
27. Kopf D, Goretzki PE, Lehnert H (2001) Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 127:143-155
28. Iino K, Oki Y, Sasano H (2000) A case of adrenocortical carcinoma associated with recurrence after laparoscopic surgery. Clin Endocrinol (Oxf) 53:243-248
29. Ushiyama T, Suzuki K, Kageyama S, Fujita K, Oki Y, Yoshimi T (1997) A case of Cushing's syndrome due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy. J Urol 157:2239
30. Schlamp A, Hallfeldt K, Mueller-Lisse U, Pfluger T, Reincke M (2007) Recurrent adrenocortical carcinoma after laparoscopic resection. Nat Clin Pract Endocrinol Metab 3:191-195 quiz 1 p following 5
31. Terzolo M, Berruti A (2008) Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 15:221-226
32. Dackiw AP, Lee JE, Gagel RF, Evans DB (2001) Adrenal cortical carcinoma. World J Surg 25:914-926
33. Chiche L, Dousset B, Kieffer E, Chapuis Y (2006) Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 139:15-27
34. Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380
35. van Ditzhuijsen CI, van de Weijer R, Haak HR (2007) Adrenocortical carcinoma. Neth J Med 65:55-60
36. Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392
37. Ahlman H, Khorram-Manesh A, Jansson S et al (2001) Cytotoxic treatment of adrenocortical carcinoma. World J Surg 25:927-933
38. Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
39. Khan TS, Imam H, Juhlin C et al (2000) Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281-1287
40. Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667-680
41. Quinkler M, Hahner S, Wortmann S et al (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93:2057-2062
42. Fassnacht M, Hahner S, Polat B et al (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504
43. Stojadinovic A, Ghossein RA, Hoos A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20:941-950
44. Harrison LE, Gaudin PB, Brennan MF (1999) Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134:181-185
45. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
46. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456
47. Ohgaki H, Kleihues P, Heitz PU (1993) p53 mutations in sporadic adrenocortical tumors. Int J Cancer 54:408-410
48. Reincke M, Karl M, Travis WH et al (1994) p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78:790-794
49. Sidhu S, Martin E, Gicquel C et al (2005) Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31:549-554
50. Sandrini R, Ribeiro RC, DeLacerda L (1997) Childhood adrenocortical tumors. J Clin Endocrinol Metab 82:2027-2031
51. Ribeiro RC, Sandrini F, Figueiredo B et al (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330-9335
52. Latronico AC, Pinto EM, Domenice S et al (2001) An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970-4973
53. Chang H, Yeung J, Qi C, Xu W (2007) Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 138:324-329
54. Sanchez-Carbayo M, Socci ND, Kirchoff T et al (2007) A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 13:3215-3220
55. Erill N, Colomer A, Verdu M et al (2004) Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 13:217-223
56. Gicquel C, Bertagna X, Gaston V et al (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
57. Gicquel C, Bertagna X, Schneid H et al (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444-1453
58. Giordano TJ, Thomas DG, Kuick R et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531
59. de Fraipont F, El Atifi M, Cherradi N et al (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic. Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829
60. Slater EP, Diehl SM, Langer P et al (2006) Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154:587-598
61. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83:1713-1720
62. Weber MM, Fottner C, Schmidt P et al (1999) Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 140:1537-1543
63. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F (2001) Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol 166:24-27
64. Skogseid B, Larsson C, Lindgren PG et al (1992) Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 75:76-81
65. Burgess JR, Harle RA, Tucker P et al (1996) Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 131:699-702
66. Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P (2007) Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg 392:437-443
67. Heppner C, Reincke M, Agarwal SK et al (1999) MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab 84:216-219
68. Zwermann O, Beuschlein F, Mora P, Weber G, Allolio B, Reincke M (2000) Multiple endocrine neoplasia type 1 gene expression is normal in sporadic adrenocortical tumors. Eur J Endocrinol 142:689-695
69. Schulte KM, Heinze M, Mengel M et al (1999) MEN I gene mutations in sporadic adrenal adenomas. Hum Genet 105:603-610
70. Schulte KM, Mengel M, Heinze M et al (2000) Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J Clin Endocrinol Metab 85:441-448 (Pubitemid 32268848)
71. Baumgartner-Parzer SM, Pauschenwein S, Waldhausl W, Polzler K, Nowotny P, Vierhapper H (2002) Increased prevalence of heterozygous 21-OH germline mutations in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 56:811-816
72. Kjellman M, Holst M, Backdahl M, Larsson C, Farnebo LO, Wedell A (1999) No overrepresentation of congenital adrenal hyperplasia in patients with adrenocortical tumours. Clin Endocrinol (Oxf) 50:343-346
73. Beuschlein F, Schulze E, Mora P et al (1998) Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors. J Clin Endocrinol Metab 83:2585-2588
74. Bossis I, Stratakis CA (2004) Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 145:5452-5458
75. Bertherat J, Groussin L, Sandrini F et al (2003) Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63:5308-5319
76. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
77. Schwindinger WF, Francomano CA, Levine MA (1992) Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune- Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156
78. Lania A, Mantovani G, Spada A (2001) G protein mutations in endocrine diseases. Eur J Endocrinol 145:543-559
79. Happle R (1986) The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 29:321-324
80. Kirschner LS (2002) Signaling pathways in adrenocortical cancer. Ann NY Acad Sci 968:222-239
81. Lyons J, Landis CA, Harsh G et al (1990) Two G protein oncogenes in human endocrine tumors. Science 249:655-659 (Pubitemid 20259082)
82. Rosenberg D, Groussin L, Bertagna X, Bertherat J (2002) cAMP pathway alterations from the cell surface to the nucleus in adrenocortical tumors. Endocr Res 28:765-775
83. Lumbroso S, Paris F, Sultan C (2002) McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab 15(Suppl 3):875-882
84. Kirschner LS, Carney JA, Pack SD et al (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26:89-92
85. Rocha KM, Forti FL, Lepique AP, Armelin HA (2003) Deconstructing the molecular mechanisms of cell cycle control in a mouse adrenocortical cell line: roles of ACTH. Microsc Res Tech 61:268-274
86. Beuschlein F, Reincke M (2006) Adrenocortical tumorigenesis. Ann NY Acad Sci 1088:319-334
87. Fragoso MC, Domenice S, Latronico AC et al (2003) Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 88:2147-2151
88. Latronico AC, Reincke M, Mendonca BB et al (1995) No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab 80:875-877
89. Light K, Jenkins PJ, Weber A et al (1995) Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sci 56:1523-1527
90. Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP, Allolio B (1997) Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 82:3054-3058
91. Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281:22429-22433
92. Collu GM, Brennan K (2007) Cooperation between Wnt and Notch signalling in human breast cancer. Breast Cancer Res 9:105
93. Clements WM, Wang J, Sarnaik A et al (2002) beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62:3503-3506
94. Kolligs FT, Bommer G, Goke B (2002) Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66:131-144
95. Clements WM, Lowy AM, Groden J (2003) Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer 3:113-120
96. Tissier F, Cavard C, Groussin L et al (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622-7627
97. Doghman M, Cazareth J, Lalli E (2008) The T cell factor/beta-catenin antagonist PKF115- 584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 93:3222-3225
98. Gaujoux S, Tissier F, Groussin L, et al (2008) Wnt/ss-catenin and cAMP/PKA signaling pathways alterations and somatic ss-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab (in press)
99. Tadjine M, Lampron A, Ouadi L, Horvath A, Stratakis CA, Bourdeau I (2008) Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clin Endocrinol (Oxf) 69:367-373
100. Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 97:11960-11965
101. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO (2006) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 281:9971-9976
102. Hino S, Tanji C, Nakayama KI, Kikuchi A (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 25:9063-9072
103. Gicquel C, Leblond-Francillard M, Bertagna X et al (1994) Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf) 40:465-477
104. Beuschlein F, Reincke M, Karl M et al (1994) Clonal composition of human adrenocortical neoplasms. Cancer Res 54:4927-4932
105. Blanes A, Diaz-Cano SJ (2006) DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Hum Pathol 37:1295-1303
106. Soon PS, Libe R, Benn DE et al (2008) Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg 247:157-164
107. Stojadinovic A, Brennan MF, Hoos A et al (2003) Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 16:742-751
108. Schmitt A, Saremaslani P, Schmid S et al (2006) IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49:298-307
109. Gupta D, Shidham V, Holden J, Layfield L (2001) Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol 9:215-221
110. Volante M, Sperone P, Bollito E et al (2006) Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 19:1563-1569
111. Kjellman M, Enberg U, Hoog A et al (1999) Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas. World J Surg 23:237-242
112. Kolomecki K, Stepien H, Bartos M, Kuzdak K (2001) Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 35:9-16
113. Parker KL, Schimmer BP (1997) Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr Rev 18:361-377
114. Luo X, Ikeda Y, Parker KL (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77:481-490
115. Bland ML, Jamieson CA, Akana SF et al (2000) Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response. Proc Natl Acad Sci USA 97:14488-14493
116. Pianovski MA, Cavalli LR, Figueiredo BC et al (2006) SF-1 overexpression in childhood adrenocortical tumours. Eur J Cancer 42:1040-1043
117. Kiiveri S, Liu J, Arola J et al (2005) Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol 233:47-56
118. Sasano H, Shizawa S, Suzuki T et al (1995) Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol 26:1154-1156
119. Parviainen H, Kiiveri S, Bielinska M et al (2007) GATA transcription factors in adrenal development and tumors. Mol Cell Endocrinol 265-266:17-22
120. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
121. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
122. Brodsky SV, Mendelev N, Melamed M, Ramaswamy G (2007) Vascular density and VEGF expression in hepatic lesions. J Gastrointestin Liver Dis 16:373-377
123. Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487-7495
124. Herve MA, Buteau-Lozano H, Vassy R et al (2008) Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol 172:167-178
125. Logan-Collins JM, Lowy AM, Robinson-Smith TM et al (2008) VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 15:738-744
126. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM, Feige JJ (2000) Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J Clin Endocrinol Metab 85:4734-4741
127. West AN, Neale GA, Pounds S et al (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608
128. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M (1993) Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 72:1386-1393
129. Kjellman M, Kallioniemi OP, Karhu R et al (1996) Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56:4219-4223
130. Sidhu S, Marsh DJ, Theodosopoulos G et al (2002) Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87:3467-3474
131. Zhao J, Speel EJ, Muletta-Feurer S et al (1999) Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 155:1039-1045
132. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P (2000) Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28:145-152
133. Stephan EA, Chung TH, Grant CS et al (2008) Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7:425-431
134. Yano T, Linehan M, Anglard P et al (1989) Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 81:518-523
135. Soon PSH, Libe R, Benn DE et al (2008) Loss of Heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg 247:157-164
136. Kjellman M, Roshani L, Teh BT et al (1999) Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab 84:730-735
137. Velazquez-Fernandez D, Laurell C, Geli J et al (2005) Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138:1087-1094